Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes With Specificities Against Tumor Associated Antigens During and After Neoadjuvant Chemotherapy and Phased Ipilimumab in Non-Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Jan 2017
At a glance
- Drugs Ipilimumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 30 Dec 2016 Planned End Date changed from 1 Nov 2020 to 1 Mar 2021.
- 30 Dec 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Mar 2018.